AGE
- AgeX Therapeutics, Inc.
()
Overview
Company Summary
AgeX Therapeutics, Inc. (AGE) is a biotechnology company that focuses on developing innovative treatments for age-related degenerative diseases. The company aims to extend human healthspan, the period in which a person remains healthy and active, by targeting the underlying mechanisms that contribute to aging.
AgeX Therapeutics employs a pluripotent stem cell technology platform known as induced Tissue Regeneration (iTR), which involves reprogramming aged or damaged cells back to a more youthful state. By utilizing this technology, the company is able to create specialized cells that have the ability to regenerate and replace damaged tissues in the body.
One of the key areas of research for AgeX Therapeutics is the development of therapeutic products to address age-related diseases associated with the degeneration of specific tissues or organs. This includes degeneration of the immune system, the musculoskeletal system, and the eye.
AgeX Therapeutics also focuses on the development of senescence-based cancer therapeutics, as senescence is a cellular state linked to both aging and cancer. By targeting senescence, the company aims to develop therapies that can prevent or treat various types of age-associated cancers.
Additionally, AgeX Therapeutics invests in the development and commercialization of other innovative biotechnologies related to aging, such as diagnostics and drug discovery tools. The company collaborates with academic institutions, research organizations, and other biotechnology companies to advance their research and bring their products to market.
Overall, AgeX Therapeutics is dedicated to advancing the field of regenerative medicine and therapeutics to address the challenges of aging and age-related diseases, with the ultimate goal of improving the overall quality of life for individuals as they grow older.